Objective. To clarify the characteristics of lymphoproliferative disorder (LPD) in patients with RA treated with MTX.
Introduction
Lymphoproliferative disorder (LPD) is a rare but wellknown complication developing in patients with RA. Previous reports revealed that RA itself is a risk factor for LPD. The prevalence of LPD is 2.0-to 5.5-fold higher in RA patients than in the general population owing to cumulative disease activity [1] . Aside from chronic rheumatoid inflammation, immunosuppressive drugs can affect the risk for LPD. MTX, the first-line DMARD [2] , can cause LPD as several studies have reported a high likelihood of developing LPD in MTX-treated patients [3, 4] . In the last WHO classification of lymphoid neoplasms, LPD developing during MTX treatment was classified as other iatrogenic immunodeficiency associated LPD [5] .
Spontaneous regression of LPD following MTX withdrawal is a singular aspect of LPD developing during MTX treatment, with an incidence of 3060% [5, 6] . However, there is no current way to identify the subset of LPD that will regress by MTX cessation. Although EBV positivity in LPD is recognized as a sign of good prognosis, LPD can incur poor prognosis despite the presence of EBV, and vice versa [5, 7] . The aim of this study was to clarify the characteristics of LPD developing during MTX treatment with spontaneous regression following MTX withdrawal.
Methods

Patients
We retrospectively reviewed medical records of all RA patients in our institution between January 1995 and December 2013 and found 33 patients diagnosed with LPD during MTX treatment. Diagnosis of LPD was performed with either of the following two definitions: pathological diagnosis (n = 25), or clinical diagnosis with findings of CT, MRI and/or [18F]-fluoro-D-glucose-PET that demonstrated lesions highly suspected to be LPD (n = 8). For each LPD case, two control RA patients without LPD matched for age, sex, RA duration and MTX dose (n = 66) were randomly selected from 681 RA patients who had been treated with MTX for >6 months in our institution as of December 2013. The study design is depicted in Supplementary Fig. S1 , available at Rheumatology Online.
This study was approved by the ethics committee of Keio University School of Medicine (approval number: 20110136). Written informed consent from patients was waived in accord with the regulation in Japan. All investigations were conducted according to the principles in the Declaration of Helsinki.
LPD assessment
LPD stage was determined with the Ann Arbor staging classification with the Cotswolds modifications [8] . Experienced pathologists in our institution performed histological evaluations to classify the cases into three categories according to the WHO classification [5] : classical Hodgkin's lymphoma, non-Hodgkin's lymphoma and unclassified LPDs. The presence of EBV genome was assessed with EBV-encoded small RNAs (EBER) using in situ hybridization. All patients stopped MTX at the time of LPD diagnosis. We retrospectively assessed the clinical course of LPD 12 weeks after MTX cessation in accordance with the revised response criteria of the International Working Group [9] . Following this assessment, patients were divided into two groups: the regressive group and the persistent group. The regressive group included patients with complete remission (n = 4) and partial remission (n = 16). The persistent group included patients with stable disease (n = 5) and progressive disease (n = 8). The definitions of those outcomes are summarized in Supplementary Table S1, available at Rheumatology online. Six patients with progressive disease were administered chemotherapy: three patients at week 2, one at week 3 and two at week 8.
Data collection
Clinical information was collected from the medical records, including background characteristics and clinical values pertinent to RA and LPD. For LPD cases, the time of MTX cessation, which was simultaneous with LPD diagnosis, was set as the baseline (0 week). Clinical and laboratory parameters were collected at the time of MTX initiation, and from 6 months prior to MTX withdrawal (À6, À4 and À2 months) to 12 weeks post-withdrawal (2, 4, 8 and 12 weeks). If RA treatment was intensified, chemotherapy was started or the patient died within the 12 weeks post-MTX withdrawal, and the last observation was carried forward so as to avoid treatment interference. In control patients, an arbitrary time point during MTX treatment was set as baseline (0 months), and clinical data were collected at the time of MTX initiation, and bimonthly around month 0 (À6, À4, À2 and 2 months).
Assessment of RA RA disease activity was assessed by tender joint count and swollen joint count. Intensification of RA treatment included an increase in corticosteroid dose or addition of other DMARDs by the attending physicians for RA aggravation.
Statistical analysis
Descriptive values are expressed as medians (range).
Comparisons of values and proportions of clinical parameters between the three groups were conducted by KruskalWallis test and chi-squared test. Comparisons between two groups were conducted by paired or unpaired Wilcoxon's test and Fisher's exact test. Results with P < 0.05 were regarded as significant. All statistical analyses were performed with JMP software v. 11.2.0 (SAS Institute Inc., Cary, NC, USA). Table 1 shows the characteristics of the regressive group (n = 20), the persistent group (n = 13) and the control group (n = 66) at baseline. No significant differences were found in the demographic characteristics, RA and LPD features among the groups. Anti-CCP positivity in the persistent group was lower than in the control group (50% vs 83%, P = 0.06). While the concomitant DMARDs and corticosteroid use were not different between the groups, TNF inhibitor (TNF-i) use was more frequent in the control group than in the regressive and progressive groups (19.7% vs 5% vs 7.7%, respectively, P = 0.06).
Results
Baseline characteristics
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TABLE 1
Characteristics of the lymphoproliferative disorder and control RA patients Laboratory data White blood cell count, median (IQR), Â10 Laboratory examinations showed significantly higher levels of lactate dehydrogenase (LDH) and CRP in the regressive and progressive groups compared with the control group (LDH, 249 vs 270 vs 197 IU/l, P < 0.01; CRP, 2.15 vs 1.21 vs 0.08 mg/dl, P < 0.01, respectively). The absolute lymphocyte number was significantly different among the regressive, progressive and control groups (497 vs 680 vs 1400/ml, respectively, P < 0.05 for all comparisons). Of note, lymphocyte count was not different between the EBER positive (n = 15) and EBER negative (n = 5) patients (480 vs 812/ml, P = 0.26). Neither the concomitant use of TNF-i nor the use or dose of corticosteroid affected lymphocyte count (data not shown).
Changes in lymphocyte count
We traced chronological changes in lymphocyte number from MTX initiation up to 12 weeks (Fig. 1A) . Lymphocyte count of the regressive group at MTX initiation and 6 months before the LPD diagnosis was lower than those of the persistent and control groups, although the difference was not statistically significant (1088 vs 1204 vs 1441/ml, P = 0.08; 815 vs 1467 vs 1316/ml, P < 0.01, respectively). The lymphocyte count of the regressive group decreased from MTX initiation to À2 months (1088792/ml, P = 0.01), and dipped from À2 months to 0 weeks (792497/ml, P = 0.04). After MTX cessation, it rapidly recovered (1214/ml at 2 weeks, 1338/ml at 4 weeks, 1380/ml at 8 weeks, 1586/ml at 12 weeks, P < 0.01 for all comparisons to 0 week) and was maintained at equivalent levels to those of the control group (1400/ml at baseline). On the other hand, lymphocyte count in the persistent group was not different from the control group from À6 to À2 months, but decreased at 0 week to lower levels than the control group (680 vs 1400/ml, P = 0.03). Levels did not change after MTX cessation (734/ml at 2 weeks, 708/ml at 4 weeks, 603/ml at 8 weeks, 620/ml at 12 weeks, P > 0.05 for all comparisons to 0 week).
We further compared changes in lymphocyte count between the regressive and persistent groups after MTX cessation. While lymphocyte count in the regressive group significantly increased reaching a peak at 12 weeks (Álymphocyte count, 1072/ml), that in the persistent group Control vs Regressive, P < 0.05; Regressive vs Persistent, P < 0.05; Control vs Persistent, P < 0.05. *P < 0.05 for the comparison with the value at week 0 in each group. LPD: lymphoproliferative disorder.
did not change (Fig. 1B) . Changes in lymphocyte count from 0 to 2 weeks in the regressive group ranged from 221 to 2301/ml, and from À226 to 151/ml in the persistent group. Hence, Álymphocyte count at 2 weeks was completely different in the two groups (Fig. 1C) , leading us to conjecture that an increase in lymphocyte count of > 220/ ml 2 weeks after MTX withdrawal indicates favourable prospects for LPD spontaneous regression.
Changes in other clinical parameters
Next, we reviewed the changes in other pertinent LPD or immune system parameters including LDH, CRP and IgG (supplementary Fig. S2 , available at Rheumatology Online). The change in LDH from 0 to 2 weeks was modestly different between the regressive group and the persistent group (À17 vs 5 IU/l, P = 0.02). The change in CRP showed the same trend but was more complicated owing to the influence of RA disease activity (data not shown). No significant change in IgG levels was found in either group.
Disease activity of RA after MTX withdrawal Changes in tender joint count and swollen joint count are shown in supplementary Fig. S3 , available at Rheumatology Online. Eight patients in the regressive group and one patient in the persistent group required RA treatment intensification. Prednisolone dose was increased in six patients in the regressive group and in one in the persistent group at between 8 and 12 weeks to a maximum of 10 mg/day. The lymphocyte count did not significantly change before and after the dose increase (16241395/ml, P = 0.66).
Discussion
The present study revealed that decrease in lymphocytes at LPD diagnosis and restoration following MTX withdrawal are associated with spontaneous regression of LPD developing during MTX treatment. A significant increase in lymphocyte count of >220/ml at 2 weeks after MTX cessation could predict spontaneous LPD regression as this cut-off value demarcated regressing LPD from non-regressing LPD.
Whereas previous studies have reported that LPD regression after MTX withdrawal can be observed in 3060% of LPD patients [5, 6] , higher rates (5990%) have been reported in recent articles from Japan [7, 10] . Likewise, 61% of our patients experienced complete or partial remission. This could be due to the immediate cessation of MTX once LPD is suspected, which is currently recommended in the Japanese guidelines for MTX treatment for RA patients [11] . Indeed, a study reported that a maximum regression effect could be achieved 8 weeks after MTX withdrawal and proposed MTX withdrawal with close observation as an acceptable LPD treatment plan [10] .
A standard management plan for LPD occurring during MTX treatment has yet to be established because the clinical course of LPD after MTX cessation is considered unpredictable. Although several studies reported EB virus positivity as a favourable sign of spontaneous regression, it is still inconclusive [5, 7] . Our study revealed that reinstatement of lymphocyte numbers following MTX cessation is relevant to spontaneous LPD regression, which corroborates the observations of a recent study [10] . Importantly, we were able to show the clear difference between the regressive and the persistent LPD, demonstrating that the increase in peripheral lymphocyte count 2 weeks after MTX withdrawal can be used as a marker to distinguish spontaneous regression from non-regression.
The significantly lower lymphocyte counts observed in LPD patients than in the clinically matched MTX-treated patients without LPD are intriguing. While lymphopenia is an independent risk of lymphoma development in patients with primary SS [12] , the tumour-induced PD-1 pathway could cause lymphocytopenia [13] . Therefore, our results showing decreased lymphocyte levels prior to LPD onset raise the question whether the decrease in lymphocyte count is a risk factor for LPD during MTX treatment, or an outcome of the development of LPD.
In addition, lymphocyte count at the MTX initiation appeared lower in the regressive group than in the persistent and the control groups. Anti-CCP positivity was inclined to be frequent in the persistent group. Whether such patient characteristics relate to the form of LPD developing during MTX treatment should be researched in future. It should be also examined whether unclassified pathological diagnosis is another feature of regressive LPD.
It has been reported that gdT lymphocytes, which exhibit anti-LPD effects via a perforin-mediated cytotoxic mechanism, are reduced by MTX [14] and that circulating lymphocyte subsets including cytotoxic CD8 + T cells and NK cells under a cancer bearing situation have specific anti-tumour function [15, 16] . It should be further discussed whether the increase in lymphocytes in our results is directly associated with LPD spontaneous regression; nevertheless, we believe that our study could shed light on the pathogenesis of spontaneous regression of LPD developing during MTX treatment. We should note the limitations of our study. First, this is a retrospective study with a small sample size, although we believe the number of patients was rather large for the rare disease. Also, the larger size of the control group might be statistically better, although matching clinical information limited the control patient sampling in our study. Second, in several patients, the diagnosis of LPD was based on clinical and radiological findings instead of pathological findings, owing to the disappearance of lesions before biopsy or a difficult approach to organs involved.
In conclusion, the present study reveals that tracking lymphocyte number pre-and post-MTX withdrawal enables the prediction of LPD prognosis in patients with RA treated with MTX. Prospective clinical and immunological research is warranted in the future.
Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.
